Literature DB >> 17072242

[Use of cabergoline in persisting Cushing's disease].

F Illouz1, S Dubois-Ginouves, S Laboureau, V Rohmer, P Rodien.   

Abstract

Cabergoline is a dopaminergic agonist with demonstrated efficiency of for the treatment of prolactin-secreting pituitary tumors. It has also been reported effective for patients with hypercortisolism uncontrolled by conventional therapies. We describe the use of cabergoline in three patients with Cushing's disease, one of them presenting a silent ACTH-secreting pituitary tumor. Those patients underwent surgery and only one has been treated with radiation therapy. However persisting hypercortisolism motivated the use of cabergoline. We describe a decrease or a normalization in hypercortisolism; for one of the subjects, tumor growth seemed to be stopped. While cabergoline can induce a suppression of cortisol secretion or a corticotroph tumor shrinkage, the sites of action remain unclear.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072242     DOI: 10.1016/s0003-4266(06)72611-7

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  5 in total

1.  Cushing's Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline.

Authors:  Omayma Elshafie; Anjum Osman; Fatima Aamer; Ali Al-Mamari; Njy Woodhouse
Journal:  Sultan Qaboos Univ Med J       Date:  2012-11-20

2.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 3.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

4.  Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.

Authors:  R Palui; J Sahoo; S Kamalanathan; S S Kar; S Selvarajan; H Durgia
Journal:  J Endocrinol Invest       Date:  2018-08-10       Impact factor: 4.256

5.  Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.

Authors:  Julia Simões Corrêa Galendi; Afonso Nogueira Simões Correa Neto; Michelle Demetres; Cesar Luiz Boguszewski; Vania Dos Santos Nunes Nogueira
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-17       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.